Different airway responsiveness profiles in atopic asthma, nonatopic asthma, and Sjögren's syndrome

Lúdvı́ksdóttir, Dóra; Janson, Christer; Björnsson, E.; Stålenheim, Gunnemar; Boman, Gunnar; Hedenström, Hans; Venge, Per; Guðbjörnsson, Björn; Valtýsdóttir, Sigrídur Th.

doi:10.1034/j.1398-9995.2000.00252.x

Cited by 56 publications

(49 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The fact that both early and late asthmatic responses are sensitive to pharmacologic agents that block FcεRI-dependent MC activation implies a pathway by which MCs can potentiate AHR (17). Of note, however, is that AHR can exist as an isolated phenotype in nonasthmatic individuals, can precede the clinical onset of asthma, and is also present in nonatopic asthmatics (18). The question of whether MCs play a role in asthma independent of IgE and sensitization to allergen remains largely unexplored.…”

mentioning

confidence: 99%

The naïve airway hyperresponsiveness of the A/J mouse is Kit -mediated

Cozzi¹,

Ackerman²,

Lundequist

et al. 2011

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

mentioning

confidence: 99%

The naïve airway hyperresponsiveness of the A/J mouse is Kit -mediated

Cozzi¹,

Ackerman²,

Lundequist

et al. 2011

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

“…Mechanisms underlying bronchial hyperresponsiveness in patients with primary Sjö gren's syndrome probably differ from those in asthmatic patients [65], but remain unknown. Chronic sputum production and recurring sinusitis are associated with severe chronic bronchiolitis in primary Sjö gren's syndrome [66].…”

Section: Connective Tissue Diseasesmentioning

confidence: 98%

“…Although systemic steroids have been proposed by some authors, it does not appear efficacious in most cases [51]. Low-dose macrolides have been proposed in subjects with bronchiolitis related to rheumatoid arthritis [41] and may be proposed in Sjö gren's syndrome [65]. Inhaled steroids and long-acting bronchodilators could be proposed in patients with bronchial hyperresponsiveness, although one study suggested that this approach is not very effective in Sjö gren's syndrome [71].…”

Section: Connective Tissue Diseasesmentioning

confidence: 99%

Small airways diseases, excluding asthma and COPD: an overview

Burgel¹,

Bergeron²,

Blic³

et al. 2013

European Respiratory Review

104

View full text Add to dashboard Cite

This review is the summary of a workshop on small airways disease, which took place in Porquerolles, France in November 2011. The purpose of this workshop was to review the evidence on small airways (bronchiolar) involvement under various pathophysiological circumstances, excluding asthma and chronic obstructive pulmonary disease. Histopathological patterns associated with small airways disease were reviewed, including cellular and obliterative bronchiolitis. Many pathophysiological conditions have been associated with small airways disease including airway infections, connective tissue diseases and inflammatory bowel diseases, bone marrow and lung transplantation, common variable immunodeficiency disorders, diffuse panbronchiolitis, and diseases related to environmental exposures to pollutants, allergens and drugs. Pathogenesis, clinical presentation, a computed tomography scan and pulmonary function test findings are reviewed, and therapeutic options are described with the objective of providing an integrative approach to these disorders.

show abstract

“…Unlike asthma, eosinophils do not seem to act on hyperresponsiveness in Sjögren's syndrome. The intensity of hyperresponsiveness is not correlated with salivary gland infiltration [69] or with exhaled nitric oxide level [71]. No difference in bronchial gland atrophy was observed between Sjögren's syndrome patients and controls [72].…”

Section: Bronchial Hyperresponsivenessmentioning

confidence: 99%

Pulmonary manifestations of Sjögren's syndrome

et al. 2016

View full text Add to dashboard Cite

In 9–20% of cases, Sjögren's syndrome is associated with various respiratory symptoms. The most typical manifestations are chronic interstitial lung disease (ILD) and tracheobronchial disease. The most common manifestation of ILD is nonspecific interstitial pneumonia in its fibrosing variant. Other types of ILD, such as organising pneumonia, usual interstitial pneumonia and lymphocytic interstitial pneumonitis, are rare. Their radiological presentation is less distinctive, and definitive diagnosis may require the use of transbronchial or surgical lung biopsy. Corticosteroid therapy is the mainstay of ILD treatment in Sjögren's syndrome, but the use of other immunosuppressive drugs needs to be determined. ILD is a significant cause of death in Sjögren's syndrome. Tracheobronchial disease is common in Sjögren's syndrome, characterised by diffuse lymphocytic infiltration of the airway. It is sometimes responsible for a crippling chronic cough. It can also present in the form of bronchial hyperresponsiveness, bronchiectasis, bronchiolitis or recurrent respiratory infections. The management of these manifestations may require treatment for dryness and/or inflammation of the airways. Airway disease has little effect on respiratory function and is rarely the cause of death in Sjögren's syndrome patients. Rare respiratory complications such as amyloidosis, lymphoma or pulmonary hypertension should not be disregarded in Sjögren's syndrome patients.

show abstract

Different airway responsiveness profiles in atopic asthma, nonatopic asthma, and Sjögren's syndrome

Cited by 56 publications

References 25 publications

The naïve airway hyperresponsiveness of the A/J mouse is Kit -mediated

The naïve airway hyperresponsiveness of the A/J mouse is Kit -mediated

Small airways diseases, excluding asthma and COPD: an overview

Pulmonary manifestations of Sjögren's syndrome

Contact Info

Product

Resources

About